Medtronic has announced the completion of their acquisition of Medicrea, a platform which uses artificial intelligence (AI) to advance spinal surgeries. Medicrea solution uses predictive modelling and algorithms which measure and digitally reconstruct a patient’s spine, forming individualised patient care.
Medicrea has over 30 products with US Food and Drug Administration (FDA) 510(K) clearance and CE Marked spinal implant technologies for use in surgeries for adult deformities, paediatric deformities and degenerative disease. This is in part powered by Medicrea’s UNiDTM ASI (Adaptive Spine Intelligence) platform, which has seen growth over this year despite restrictions imposed by COVID-19.
Christopher Ames, director of spinal tumor and spinal deformity surgery at University of California San Francisco, USA, said, “Through the power of predictive models, data collection and machine learning, a unique capability is created, allowing for a continuous cycle of improvement. Physicians will have augmented eyes through surgical navigation, augmented hands with robotics, and most importantly, augmented intelligence through full integration with machine intelligence impacting all aspects of the care pathway. This type of technology will likely lead to safer procedures and more reliable outcomes while preventing costly revision surgery. It is rewarding to see the spine industry fully embracing these new capabilities and investing in the future.”
This acquisition further expands Medtronic’s portfolio of personalized implants and AI-driven planning and prediction capabilities. Throughout 2020, Medtronic have made six other acquisitions in the field of AI, machine learning, and predictive analytics.